Tabernanthalog (TBG) is a synthetic ibogaine analog built to retain the neuroplasticity and anti-addictive properties of ibogaine while removing the two main liabilities: hERG channel blockade (cardiotoxic) and full 5-HT2A agonism (hallucinogenic). The structural redesign replaces full 5-HT2A agonism with partial agonism, preserving the plasticity window that psychedelics open at 5-HT2A without the subjective effects. TrkB transactivation drives BDNF signaling, increasing dendritic spine density and promoting structural synaptic remodeling.
The off-season rationale is that the active season runs sustained AMPA potentiation (TAK-653), high glutamate tone, and repeated learning-task demands — all of which wear dendritic spines over time. Tabernanthalog rebuilds that structure at the level of the synapse rather than receptor pharmacology. This is what Cerebrolysin does via peptide neurotrophic factor delivery; Tabernanthalog achieves something similar pharmacologically and is considerably easier to source. If stacking with Cerebrolysin, run sequentially rather than simultaneously — both drive plasticity and there’s no obvious benefit to doubling up in the same window. Human dosing is not established; early compound with no long-term human data yet. Keep it to a short course.